BASEL, SWITZERLAND--(Marketwire - November 13, 2008) - Basilea Pharmaceutica Ltd. announces that ceftobiprole (Zevtera™), the first-in-class anti-MRSA broad-spectrum cephalosporin, has obtained regulatory approval from Swissmedic for the treatment of complicated skin and soft tissue infections including diabetic foot infections.
